WallStSmart

Monte Rosa Therapeutics Inc (GLUE)vsBeOne Medicines AG (ONC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

BeOne Medicines AG generates 9294% more annual revenue ($6.61B vs $70.33M). ONC leads profitability with a 13.9% profit margin vs -186.2%. ONC earns a higher WallStSmart Score of 68/100 (B-).

GLUE

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: 0.02

ONC

Strong Buy

68

out of 100

Grade: B-

Growth: 10.0Profit: 7.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GLUE.

ONCUndervalued (+80.8%)

Margin of Safety

+80.8%

Fair Value

$1828.58

Current Price

$390.94

$1437.64 discount

UndervaluedFair: $1828.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GLUE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
325.8%10/10

Revenue surging 325.8% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

ONC4 strengths · Avg: 9.3/10
Revenue GrowthGrowth
33.8%10/10

Revenue surging 33.8% year-over-year

EPS GrowthGrowth
212.5%10/10

Earnings expanding 212.5% YoY

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.718/10

Growing faster than its price suggests

Areas to Watch

GLUE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$880.99M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

Free Cash FlowQuality
$-42.54M2/10

Negative free cash flow — burning cash

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
51.2x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GLUE

The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.71 suggests the stock is reasonably priced for its growth.

Bear Case : GLUE

The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 51.2x leaves little room for execution misses.

Key Dynamics to Monitor

GLUE profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.

GLUE carries more volatility with a beta of 1.38 — expect wider price swings.

GLUE is growing revenue faster at 325.8% — sustainability is the question.

ONC generates stronger free cash flow (474M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (68/100 vs 36/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monte Rosa Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.

Visit Website →

BeOne Medicines AG

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?